US Stock MarketDetailed Quotes

ANL Adlai Nortye

Watchlist
  • 7.260
  • -0.440-5.71%
Close May 31 16:00 ET
  • 7.400
  • +0.140+1.93%
Post 19:53 ET
267.90MMarket Cap-2552P/E (TTM)

About Adlai Nortye Company

Adlai Nortye Ltd. operates as a clinical-stage biopharmaceutical company focused on the development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018 and is headquartered in Hangzhou, China.

Company Profile

SymbolANL
Company NameAdlai Nortye
Issue Price23.00
Founded2018
CEOMr. Yang Lu
MarketNASDAQ
Employees127
Securities TypeDR
ADS Ratio1.0 : 3.0
Fiscal Year Ends12-31
AddressBuilding 6 & 8,1008 Xiangwang Street,Yuhang District
CityHangzhou
ProvinceZhejiang
CountryChina
Zip Code311100
Websitehttp://www.adlainortye.com

Company Executives

  • Name
  • Position
  • Salary
  • Yang Lu
  • Chief Executive Officer and Chairman of the Board
  • --
  • Dr. Lars Erik Birgerson
  • Director, President and Chief Medical Officer; Chief Executive Officer, U.S. Subsidiary
  • --
  • Wei Vicky Zhang
  • Chief Financial Officer
  • --
  • Dr. Kaiyang Tang
  • Senior Vice President and Global Head, Clinical Operations
  • --
  • Dr. Victoria Elizabeth Demby
  • Senior Vice President and Global Head, Regulatory Affairs
  • --
  • Dr. Ping Ji
  • Director
  • --
  • Dr. Cheguo Cai
  • Independent Director
  • --
  • Shaorong Liu
  • Independent Director
  • --
  • Ming Lun Alan Tse
  • Independent Director
  • --
  • Dr. Archie Tse
  • Head of Research and Development
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg